Navigation Links
Preclinical Study Presented at AACR Annual Meeting Shows Peregrine's Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
Date:4/15/2008

, researchers irradiated an aggressive and metastatic strain of breast cancer cells coated with an immunocytokine comprised of the bavituximab equivalent 2aG4 fused with IL-2, which stimulates the immune system by activating anti-tumor T-cells. Mice were administered four doses of these irradiated immunocytokine-coated cells before receiving an implant of live breast cancer cells. Eight of the 10 mice, or 80%, receiving prophylactic pre-treatment with irradiated breast cancer and immunocytokine cells did not develop any tumors and remained tumor-free through 270 days post-treatment. Among control animals receiving either 2aG4 alone or IL-2 fused to a non-specific antibody, only two of 10 mice, or 20%, remained tumor-free. All of the control animals receiving irradiated breast tumor cells alone developed lethal tumors.

Dr. Philip Thorpe, an author of the study who is an advisor to Peregrine and a professor of pharmacology at UT Southwestern noted, "This study provides further evidence that our anti-PS antibodies have the potential to reverse the immunosuppressive effects of PS on some tumor cells, in addition to their well-documented ability to selectively target and destroy tumor blood vessels. We look forward to further investigating the clinical utility of these unique anti-cancer properties in combination with other anti-cancer regimens."

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab helps mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase Ib pilot trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objectiv
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling
2. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
3. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
4. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
6. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
7. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
8. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
9. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
10. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Ohio, July 30, 2015 Mettler-Toledo International Inc. ... for 2015.  Provided below are the highlights: ... quarter compared with the prior year. Reported sales decreased ... the quarter. , Net earnings per diluted share ... the prior-year period. Adjusted EPS was $2.80 , ...
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 /PRNewswire/ ... that it will release its second quarter 2015 financial ... 6, 2015.   In conjunction with the release, the ... community at 5:00 p.m. Eastern Time on ... results of the quarter and other business developments. ...
(Date:7/30/2015)... , July 30, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ ... into non-exclusive Development Agreements with Dexcom, Inc. to ... pumps with the Dexcom G5 and G6 continuous ... next generation pump platform with Dexcom,s future CGM ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... Tarsa Therapeutics today announced that the Phase III ORACAL ... treatment of postmenopausal osteoporosis was successfully concluded and yielded ... used to support a New Drug Application (NDA) submission ... the fourth quarter of 2011, based on the study ...
... YORK, March 24, 2011 Reportlinker.com announces that ... its catalogue: RNAi Drug ... http://www.reportlinker.com/p0461653/RNAi-Drug-Delivery-Technologies-and-Global-Markets.html THIS ... to how the RNAi (ribonucleic acid interference) technologies market ...
Cached Medicine Technology:Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis 2Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis 3Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis 4Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 2Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 3Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 4Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 5Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 6Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 7Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 8Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 9Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 10Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 11Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 12Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 13Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 14
(Date:8/1/2015)... Angeles, CA (PRWEB) , ... August 01, 2015 , ... Have you ever wondered what ... up when you hear the word “Karma.” , Vedic tradition, which gave birth to ... Karma is one of the central concepts of this tradition. According to the wisdom of ...
(Date:8/1/2015)... ... ... Calvary Hospital today announced that it is embarking on a yearlong restoration of ... this Torah – dating from 1880 – back to kosher status, so that it ... No. 515, from the town of Taus-Domazlice, is on permanent loan to Calvary from ...
(Date:8/1/2015)... ... August 01, 2015 , ... Brig and Lita Hart, icons of the network ... their Healthy Home mission with the HOPE Movement of EvolvHealth. In what has been ... companies have agreed to join their missions of purpose together to change the course ...
(Date:8/1/2015)... ... August 01, 2015 , ... On Tuesday, July 28th, ... who are thought to have been behind the attack on Anthem Inc. which resulted ... zero day exploits, watering hole attacks and spear phishing campaigns. , For ...
(Date:8/1/2015)... ... August 01, 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe ... the very first small business donation to kick off the campaign for healing and ... Her legacy includes a complete line of raw, organic hair care products, as well ...
Breaking Medicine News(10 mins):Health News:Nithyananda Yoga Foundation to Conduct Global Webinar on Karma at No Charge on August 1st 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:March4thforWellBeing Foundation Kickoff 2
... from McMaster University in their clinical trial reported in ... such as amiodarone combined with beta blockers such as ... ventricular arrhythmia patients undergoing Implantable Cardioverter defibrillator (ICD). ICD ... treat fatal cases of ventricular arrhythmias, but these shocks ...
... some others see an endless hope. This is the secret ... another breast cancer survivor, who now has a success story ... is now trying to publish her autobiography and screen a ... determination the assistant news editor at Doordarshan television here displayed ...
... University says that regular exposure to a cacophony of sound ... tumor called as acoustic neuroma. //Eventually, people with this tumor ... this tumor on the cranial nerve that is responsible for ... ,The symptoms of this tumor are typically a loud ringing ...
... U.S. workers have been found to work under the ... by the Research Institute on Addictions (RIA) of the ... employed in different agencies were interviewed through telephone to ... impairment of work, over the past 12 months. The ...
... should avoid travelling to Turkey after seven confirmed cases of ... on Sunday // . ,Turkey is the sixth ... from poultry to people, the first human infections outside eastern ... from travelling to Turkey, especially to the eastern province of ...
... bacteria, previously known to exist in radioactive waste, hot ... found to reside inside the human stomach. // This ... gastrointestinal diseases and newer treatment strategies. ,The ... ago, has been largely blamed for causing peptic ulcers. ...
Cached Medicine News:Health News:Life Beyond Cancer - Delhi Woman Tells How 2Health News:Nearly 15% Of U.S. Workers Work Under The Influence Of Alcohol 2Health News:Russia warns against travel to Turkey, Iran closes border 2
... blood gas and electrolyte analyser with reusable ... upon our well established and successful Critical ... perform up to 50 tests form a ... , ,The OPTI R uses a combination ...
... Analysis Kit incorporates detection of T-wave alternans ... DMS Holter analysis tools. Premier 12 makes ... less than 10 seconds and provides visualization ... and validation. The TWA algorithm detects two ...
Velcro® Tracheostomy tube holders are available in Adult, pediatric, and infant sizes....
... Your patient will be more comfortable, ... tracheostomy tube stabilization more secure and to ... tying and untying of twill ties, consider ... adult and neonate/infant sizes, the narrow fastener ...
Medicine Products: